Company Analysis

Arrowhead Pharmaceuticals, Inc. (ARWR)

Nasdaq: ARWR · Pharmaceutical Preparations · Pasadena, CA · filing with the SEC since 1998
Grade4.7
◀ Past 5.5● Present 4.8▶ Future 4.0
1 est.

Who runs Arrowhead Pharmaceuticals, Inc.

Officers and directors as they report to the SEC on Forms 3, 4 and 5, named as filed
Chief executive, as filed
Anzalone Christopher Richard
Chief Executive Officer. First filing Jan 2008, latest Jan 5, 2026, 37 filings in all.
Officers reporting now
4
of 12 people with a filing in the last fifteen months
Directors reporting now
8
24 people on the record since 2006
Officerssales are open-market, Sep 30, 2025 to Sep 30, 2026
NameTitle as filedFirst filingLatest filingSales, 12 months
Apel Daniel JosephChief Financial OfficerAug 2025Apr 24, 20263 · $900,000
Hamilton James CChief Medical OfficerNov 2020Apr 24, 202610 · $4.6M
O'Brien PatrickCOODec 2014Jan 8, 202612 · $3.1M
Anzalone Christopher RichardChief Executive OfficerJan 2008Jan 5, 202625 · $24.0M
Directorssales are open-market, Sep 30, 2025 to Sep 30, 2026
NameRoleFirst filingLatest filingSales, 12 months
Olukotun Adeoye YdirectorSep 2020Aug 20, 20264 · $900,000
Perry Michael SdirectorJan 2012Aug 20, 20262 · $2.0M
Cohen Matthew GregorydirectorJun 2026Jun 17, 2026none
Lu HongbodirectorMar 2024May 14, 20261 · $200,000
Ferrari MaurodirectorNov 2010Dec 30, 20252 · $1.0M
Vakiener VictoriadirectorMay 2022Dec 23, 20253 · $700,000
Waddill William D.directorDec 2017Dec 23, 20253 · $600,000
Ingram Douglas SdirectorFeb 2025Dec 18, 2025none
Earlier names on the record12, newest filing first

A person is listed as reporting now after a filing in the last fifteen months. The record shows when someone last filed; it does not say why they stopped. Each name links to the filings on sec.gov.

SI Assistanton ARWR · research, not advice